ClinicalTrials.gov
public full text
Public Domain
ANAVEX2-73 for Treatment of Early Alzheimer's Disease
Phase 2b/3 48-week study to evaluate the effects of ANAVEX2-73 on cognition and function after 48 weeks of daily treatment. Additional outcome measures include refined measures of sleep, behavioral and psychological symptoms typically observed in AD, changes in daily functioning of participants and changes in caregiver burden, as well as changes in quality of life measures of both, patients and caregivers during treatment with ANAVEX2-73.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- ANAVEX2-73 Study in Parkinson's Disease Dementia#850469
- SIESTA: Sleep Intervention to Enhance Cognitive Status and Reduce Beta Amyloid#886116
- Support, Monitoring, and Reminder Technology for Mild Dementia (SMART4MD) for People With Mild Cognitive Impairment and Their Informal Caregivers: Cost-Effectiveness Analysis.#266821
- Mild Cognitive Impairment and Obstructive Sleep Apnea (2012-2014)#377832
- Sleep disturbances and risk of Alzheimer's disease: a systematic review and meta-analysis of longitudinal cohort studies.#449802
Record · ID 889613
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive